An observational cohort study just published on the peer-reviewed journal Cancer concluded that the costs of breast cancer chemotherapy vary widely in the United States, even among treatment regimens with similar efficacy, and that patients [more]
Is there too much hype surrounding personalized oncology? An article just published on The New England Journal of Medicine (available only to subscribers) essentially invites to use more caution: «There should be a clear message to [more]
Living high in the Cretan mountains, breathing fresh air, walking along shepherds’ paths, eating fresh fruits and vegetables may sound like the healthiest way of life. Unfortunately this is not the case in Crete, where [more]
«There is strong evidence that much of the information on adverse events remains unpublished and that the number and range of adverse events is higher in unpublished than in published versions of the same study»: [more]
When discussing about therapies, particularly in oncology, affordability needs to be addressed as one of the top priorities, along with safety and efficacy of the intervention, and quality and consistency of the evidence: this is [more]
The call for submissions for the 2016 edition of the Cancer World Journalism Award is open: outstanding pieces of journalism that contributed to reshape the way we think about cancer will be awarded a prize of [more]
The Journal of Medical Ethics recently published the results of an Australian survey involving 96 physicians from 10 medical specialties who were asked why patients at the end of life are often prescribed treatments that [more]
Health journalists from all over Europe are invited to apply for one of the 12 fellowships to attend the European Cancer Congress ECCO2017, which will be held in Amsterdam from 27-30 January 2017, with the [more]
Cancer diagnosis seems associated with an increased risk of some mental health disorders, and increased use of psychiatric medications, according to a Swedish cohort study published on JAMA Oncology. The study by Donghao Lu and [more]
A new model of active surveillance (AS) for patients with low-risk prostate cancer proved to be effective in helping clinicians to appropriately select and follow patients preventing the risk of overtreatment, according to the results [more]